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**Value of the data**•This data characterizes the distribution of Cyr61 expression in skin lesion of patients with psoriasis vulgaris.•These data could be used for developing improved strategy in the treatment of psoriasis.

1. Data {#s0005}
=======

The dataset of this article provides information on the Cyr61 and IL-8 expression in skin lesion in psoriasis patients ([Fig. 1](#f0005){ref-type="fig"}, [Fig. 2](#f0010){ref-type="fig"}) and the change of the production of Cyr61 by specific siRNA *in vitro* and anti-Cyr61mAb *in viv*o ([Fig. 3](#f0015){ref-type="fig"}, [Fig. 4](#f0020){ref-type="fig"}).

2. Experimental design, materials and methods {#s0010}
=============================================

2.1. Immunohistochemistry analysis of Cyr61 expression {#s0015}
------------------------------------------------------

Normal and lesional skin from human donors and mice were fixed in 4% paraformaldehyde, embedded in paraffin and sectioned. For immunohistochemistry, skin samples from patients were stained with anti-Cyr61 mAb at a concentration of 1:200 followed by HRP conjugated goat anti-mouse secondary antibody [@bib1][@bib2].

2.2. RNAi knockdown of gene expression {#s0020}
--------------------------------------

Cyr61, IL-1β and TNF-α small interfering RNA (siRNA, [Table S2](#s0035){ref-type="fn"}; see [Supporting information](#s0035){ref-type="fn"}) were designed and synthesized at Shanghai Genepharma (Shanghai, China) and gene knockdowns were performed as previously reported [@bib3]. HaCaT cells were cultured in 24-well plates. A transfection mixture of siRNA oligonucleotides and Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA) in serum-free medium was added to medium-aspirated cells for 4 h. Then, the medium was replaced with complete DMEM containing 10% fetal bovine serum for additional 24 h incubation.

2.3. Establishment and treatment of IMQ-induced psoriasis-like skin inflammation model in mice {#s0025}
----------------------------------------------------------------------------------------------

For induction of the psoriasis-like skin inflammation model, mice received a daily topical dose of 62.5 mg of IMQ cream (5%) (Aldara, 3M Pharmaceutical, UK) on the shaved back and the right ear, representing a daily dose of 3.125 mg of the active compound. Control mice were treated similarly with vaseline (Vaseline Lanette cream, Fagron). Mice received intraperitoneal injections of 200 μg/day of either anti-Cyr61 mAb 093G9 or control IgG1 (Millipore, Billerica, MA, USA) 2 days after IMQ treatment. After16 days later mice were sacrificed and skin samples were collected and inspected [@bib4].
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![The occurrence and distribution of Cyr61 expression in skin lesion of patients with psoriasis vulgaris. The epidermal positive staining of Cyr61 varied from patient to patient: (a) darker staining in stratum basale, (b) darker staining in upper epidermal layers, (c) moderate staining in stratum spinosum, (d) isotype control. Bar 100 μm, Magnification ×100.](gr1){#f0005}

![Representative immunofluorescent staining of Cyr61 and IL-8 in the lesional skin of psoriasis patient. Bar 100 μm.](gr2){#f0010}

![The identification of specific siRNA of Cyr61. The siRNA of Cyr61 was identified in HaCaT cells, which could reduce Cyr61 expression by about 50% at mRNA levels. \*\**P*\<0.01.](gr3){#f0015}

![Symptoms in psoriasis-like mice treated with 093G9 were significantly inhibited by blocking Cyr61. The multilayer silvery white scales in the back skin and the incrassation of the ears were decreased after blocking Cyr61 expression. \*\**P*\<0.01.](gr4){#f0020}
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